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Cigarette smoking (CS) continues to be a major health hazard, and it contributes significantly
to cardiovascular morbidity and mortality. Cigarette smoking impacts all phases of athero-
sclerosis from endothelial dysfunction to acute clinical events, the latter being largely
thrombotic. Both active and passive (environmental) cigarette smoke exposure predispose to
cardiovascular events. Whether there is a distinct direct dose-dependent correlation between
cigarette smoke exposure and risk is debatable, as some recent experimental clinical studies
have shown a non-linear relation to cigarette smoke exposure. The exact toxic components of
cigarette smoke and the mechanisms involved in CS-related cardiovascular dysfunction are
largely unknown, but CS increases inflammation, thrombosis, and oxidation of low-density
lipoprotein cholesterol. Recent experimental and clinical data support the hypothesis that
cigarette smoke exposure increases oxidative stress as a potential mechanism for initiating
cardiovascular dysfunction. (J Am Coll Cardiol 2004;43:1731–7) © 2004 by the American
College of Cardiology Foundation
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dpidemiologic studies strongly support the assertion that
igarette smoking (CS) in both men and women increases
he incidence of myocardial infarction (MI) and fatal
oronary artery disease (CAD) (1–11). Even low-tar ciga-
ettes and smokeless tobacco have been shown to increase
he risk of cardiovascular events in comparison to non-
mokers (12,13). Furthermore, passive smoking (environ-
ental tobacco exposure) with a smoke exposure about
ne-hundredth that of active CS is associated with approx-
mately a 30% increase in risk of CAD, compared with an
0% increase in active smokers (14,15). Thus, the evidence
inking cigarette smoke exposure with cardiovascular disease
s clearly present, yet the exact components of cigarette
moke and the mechanisms responsible for this association
ave not been clearly elucidated. This article updates the
resent clinical and experimental observations on the po-
ential pathobiology and mechanisms involved in smoking-
elated cardiovascular disease (Fig. 1).
HYSICAL AND BIOCHEMICAL
ROPERTIES OF CIGARETTE SMOKE
onventionally, cigarette smoke is divided into two phases:
tar phase and a gas phase. The tar or particulate phase is
efined as the material that is trapped when the smoke
tream is passed through the Cambridge glass-fiber filter
hat retains 99.9% of all particulate material with a size
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Manuscript received September 24, 2003; revised manuscript received Decembers8, 2003, accepted December 23, 2003.0.1 m (16). The gas phase is the material that passes
hrough the filter. The particulate (tar) phase of cigarette
moke contains 1017 free radicals/g, and the gas phase
ontains 1015 free radicals/puff (16). The radicals associ-
ted with the tar phase are long-lived (hours to months),
hereas the radicals associated with the gas phase have a
horter life span (seconds) (16–18).
Cigarette smoke that is drawn through the tobacco into
n active smoker’s mouth is known as mainstream smoke.
idestream cigarette smoke is the smoke emitted from the
urning ends of a cigarette. Mainstream cigarette smoke
omprises 8% of tar and 92% of gaseous components (16).
nvironmental tobacco smoke results from the combination
f sidestream smoke (85%) and a small fraction of exhaled
ainstream smoke (15%) from smokers (19). Sidestream
igarette smoke contains a relatively higher concentration of
he toxic gaseous component than mainstream cigarette
moke (14). Of all the known constituents, nicotine, a
omponent of the tar phase, is the addictive substance of
igarette smoke (20).
S AND ATHEROSCLEROSIS:
LINICAL AND EXPERIMENTAL OBSERVATIONS
igarette smoking predisposes the individual to several
ifferent clinical atherosclerotic syndromes, including stable
ngina, acute coronary syndromes, sudden death, and
troke. Aortic and peripheral atherosclerosis are also in-
reased, leading to intermittent claudication and abdominal
ortic aneurysms (1).
Various clinical imaging techniques have been utilized to
irectly ascertain the relationship between CS and athero-
clerosis. Early studies associated pack years of smoking
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Smoking and Cardiovascular Disease Update May 19, 2004:1731–7ith the severity of angiographically determined atheroscle-
osis (21–23). Cigarette smoking was also found to be an
ndependent predictor of new coronary lesion formation in
he Canadian Coronary Atherosclerosis Intervention trial
24). As angiography is an insensitive indicator of the
mount or progression of atherosclerosis, other techniques
ave been utilized to assess atherosclerotic changes associ-
ted with cigarette smoke exposure. Thoracic aortic athero-
clerosis as assessed by transesophageal echocardiography
as increased in cigarette smokers (25). It has also been
eported that both active and passive smoking are associated
ith a consistent increase in intimal-medial thickness of the
arotid artery as assessed by carotid ultrasound (26,27).
Vasomotor dysfunction, inflammation, and modification
f lipids are integral components for the initiation and
rogression of atherosclerosis. These components precede
he apparent structural and clinicopathologic manifestations
f atherosclerosis (28,29). The following sections address
he present knowledge regarding the effects of CS on these
omponents of atherogenesis.
asomotor dysfunction. Impairment of vasodilatory func-
ion is one of the earliest manifestations of atherosclerotic
hanges in a vessel. In both animal and human models,
everal studies have demonstrated that both active and
assive cigarette smoke exposure were associated with a
ecrease in vasodilatory function (30–40). In humans,
igarette smoke exposure impaired endothelium-dependent
asodilation (EDV) in macrovascular beds such as coronary
nd brachial arteries and in microvascular beds (30–35).
Nitric oxide (NO), a free radical, is primarily responsible
or the vasodilatory function of the endothelium (41). Using
igarette smoke extract (CSE) or isolated components such
s nicotine, multiple in vitro studies have found that CS was
ssociated with decreased NO availability (36–38). Because
here are numerous known and unknown components of
igarette smoke whose metabolic fate in the human body is
nknown, an appropriate in vitro model of CS exposure
emains to be established. In an attempt to produce a more
hysiologic in vitro model, our group has incubated endo-
helial cells with sera from smokers. Utilizing this model,
arua et al. (31,39) demonstrated that exposure to smokers’
era decreased NO availability from both human umbilical
Abbreviations and Acronyms
CAD  coronary artery disease
CO  carbon monoxide
CS  cigarette smoking
CSE  cigarette smoke extract
EDV  endothelium-dependent vasodilation
HUVECs  human umbilical vein endothelial cells
LDL  low-density lipoprotein
MI  myocardial infarction
NO  nitric oxide
TF  tissue factor
TFPI-1  tissue factor pathway inhibitor-1ein endothelial cells (HUVECs) and human coronary srtery endothelial cells by altering the expression and activ-
ty of the endothelial NO synthase enzyme. A significant
orrelation existed between flow-mediated brachial artery
DV and NO availability from cultured HUVECs exposed
o serum from the same individuals (31). Similarly, other
tudies utilizing an in vivo infusion of L-NMMA have
ndirectly demonstrated that the reduced EDV associated
ith smoking was attributable to a decreased NO availabil-
ty (33,40).
Not only is NO a vasoregulatory molecule, it helps regulate
nflammation, leukocyte adhesion, platelet activation, and
hrombosis (41). Therefore, an alteration in NO biosynthesis
ould have both primary and secondary effects on the initiation
nd progression of atherosclerosis and on thrombotic events.
nflammation. The inflammatory response is an essential
omponent in the initiation and evolution of atherosclerosis.
everal studies have indicated that CS causes about a 20% to
5% increase in the peripheral blood leukocyte count (17).
n vivo, CS is associated with an increased level of multiple
nflammatory markers including C-reactive protein,
nterleukin-6, and tumor necrosis factor alpha in both male
nd female smokers (42–45).
Local recruitment of leukocytes on the surface of endo-
helial cells is an early event in atherosclerosis. Elevations of
arious proinflammatory cytokines increase leukocyte-
ndothelial cell interaction leading to leukocyte recruitment.
ndeed, soluble VCAM-1, ICAM-1, E-selectin levels are
igher in smokers (43,46). Cigarette smoking also causes
ctivation of proatherogenic molecules leading to alteration
n cell-cell interactions. Cigarette smoking extract exposure
as associated with a 70% to 90% increase in adherence
etween human monocytes and HUVECs in culture attrib-
table to the increased expression of adhesion molecules on
he surface of both monocytes and HUVECs (47). Expo-
ure to CSE increased by 200% the rate of transendothelial
igration of monocyte-like cells across a HUVEC mono-
ayer (48). Monocytes isolated from smokers increased
xpression of the integrin CD 11b/CD 18, which aug-
ented the adhesiveness of the monocytes to HUVECs in
ulture (49). Similarly, Adams et al. (50), exposing human
onocytes and HUVECs to smokers’ serum, found a
ignificant increase in adhesion between these cells, which
as associated with increased expression of ICAM-1 on
UVECs. Thus, CS fuels the fire of inflammation in the
lood and at the vessel wall.
odification of lipid profile. Cigarette smoking could
romote atherosclerosis, in part, by its effects on lipid
rofile. Smokers have significantly higher serum cholesterol,
riglyceride, and low-density lipoprotein (LDL) levels, but
igh-density lipoprotein is lower in smokers than in non-
mokers (51). The mechanisms responsible are not clearly
lucidated, and the role of dietary differences between
mokers and non-smokers is unknown. The triglyceride/
igh-density lipoprotein abnormalities have recently been
uggested to be related to insulin resistance. In fact, it has
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etween CS and cardiovascular disease (52).
Cigarette smoking also increases oxidative modification
f LDL. Circulating products of lipid peroxidation and
utoantibody titers to oxidized LDL are significantly in-
reased in smokers (53). In 1988, Yakode et al. (54)
eported that exposure to CSE caused a modification of
igure 1. Potential pathways and mechanisms for cigarette smoking-media
epresent the probable central mechanisms in the complex pathophysiology
eroxide; METC  mitochondial electron transport chain; NADPH  n
ynthase; ONOO  peroxinitrite; O2
  superoxide.DL, which was actively taken up by the macrophages to porm foam-cells in culture. Frei et al. (55) observed that
xposure of human plasma to the gas phase of cigarette
moke caused oxidative modification of plasma LDL. Fur-
hermore, HUVECs isolated from smokers significantly
ncreased oxidative modification of LDL compared with
UVECs isolated from non-smokers (56). Cigarette smoke
xtract exposure may also decrease the plasma activity of
rdiovascular dysfunction. The bold boxes and arrows in the flow diagram
garette-smoking-mediated athero-thrombotic disease. H2O2  hydrogen
amide adenine dinucleotide phosphate reduced form; NOS  nitric oxideted ca
of ci
icotinaraoxonase, an enzyme that protects against LDL oxida-
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Smoking and Cardiovascular Disease Update May 19, 2004:1731–7ion (57). More recently, in a hyperlipidemic rabbit model,
njection of CSE accelerated atherosclerosis through oxida-
ive modification of LDL (58).
enetic predisposition. Recently, genetic predisposition
as found to influence the development of atherogenesis in
ndividuals exposed to cigarette smoke. The intersubject
ariability in the atherosclerotic process in smokers may be
artially mediated by genetic variants. Either CYP1A1
SP polymorphism or certain endothelial NO synthase
ntron 4 polymorphisms increased the susceptibility to
igarette smoke exposure-related atherosclerotic diseases
ncluding multi-vessel CAD and MI (59,60). However, at
resent, the importance of these genetic variants is un-
nown, as their prevalence in the entire population of
igarette smokers has not been determined.
S AND THROMBOSIS—CLINICAL
ND EXPERIMENTAL OBSERVATIONS
igarette smoking is associated with an increased incidence
f acute MI. Cessation of smoking significantly reduces this
isk over a one- to three-year period with an exponential
ecline approaching the risk in ex-smokers within five years
f cessation (61,62). Recent data indicate an immediate
eduction in thrombotic events with smoking cessation. A
reliminary, oral presentation study (presented by Sargent,
hepard, and Glantz at the 52nd Annual American College
f Cardiology Conference in March 2003) reported that a
itywide smoking ban in public places over a six-month
eriod in Helena, Montana, reduced the incidence of acute
I by 60% during that time period. Furthermore, patho-
ogic studies of sudden coronary death indicate that CS
ncreased the risk of plaque rupture and acute thrombosis of
lipid-rich, thin-capped atheroma in men; in female
mokers, the prevailing mechanism was plaque erosion with
uperimposed thrombosis (63,64). Acute cigarette smoke
xposure may also increase coronary artery vascular resis-
ance reducing coronary blood flow (65). Smoking may also
e a risk factor for coronary vasospasm (66).
The prothrombotic effects of exposure to cigarette smoke
ave been repeatedly demonstrated to cause alterations in
latelet function, antithrombotic/prothrombotic factors,
nd fibrinolytic factors. The following sections address the
resent knowledge regarding these effects.
latelet dysfunction. Platelets isolated from smokers ex-
ibited an increased stimulated as well as spontaneous
ggregation (67,68). After exposure to smokers’ serum,
latelets isolated from non-smokers demonstrated hyperag-
regability (69). Cigarette smoking may decrease availability
f platelet-derived NO and decrease platelet sensitivity to
xogenous NO, leading to increased activation and adhesion
70,71).
lteration of antithrombotic and prothrombotic factors.
urrent smokers have higher fibrinogen levels that correlate
ith the number of cigarettes smoked. Ex-smokers have
brinogen levels similar to non-smokers (72,73). Alter- ttions of tissue factor (TF) and TF pathway inhibitor-1
TFPI-1) and a consequent increase in thrombotic potential
ave also been documented. Human umbilical vein endo-
helial cells exposed to serum from chronic smokers showed
significantly decreased TFPI-1 level and relatively higher
ut nonsignificant increase in TF level in culture (74). An
ncreased TF immunoreactivity and an increase in TF
ctivity were observed in atherosclerotic plaques isolated
rom apoE/ mice exposed to half of a non-filtered
esearch cigarette five days a week, for eight weeks (75). In
mokers 2 h after smoking two cigarettes, an increase in
irculating TF activity has also been reported in human
lasma (76). Furthermore, higher red blood cell counts,
ematocrits, blood viscosity, and an ongoing inflammatory
rocess potentiate the prothrombotic process associated
ith smoke exposure (14,17,20).
lteration in fibrinolysis. Human umbilical vein endothe-
ial cells exposed to chronic smoker’s serum have significant
ecreases in both basal and substance-P-stimulated t-PA
elease in culture with a significant alteration in t-PA/
AI-1 molar ratio (74). Similarly, decreased plasma t-PA
ntigen and activity were observed in smokers in samples
solated from brachial and coronary arteries after pharma-
ologic stimulation (77,78).
Therefore, CS is associated with dysfunctional thrombo-
emostatic mechanism(s) that promote the initiation and/or
ropagation of thrombus formation and limit its effective
issolution.
ACTORS AND MECHANISMS RESPONSIBLE
OR SMOKING-MEDIATED VASCULAR DYSFUNCTION
igarette smoke contains over 4,000 known components, of
hich only a few components have been examined in
solation. Carbon monoxide (CO) is one such component,
ut its effects on athero-thrombotic disease have been
quivocal. An earlier study suggested that CO could be
esponsible for smoking-related cardiovascular alterations
79). However, more recent data suggest that CO from
igarette smoke was an unlikely cause for atherosclerosis or
hrombus (80–82). Polycyclic aromatic hydrocarbons found
n the tar fraction of cigarette smoke have also been studied,
nd these components, at least in experimental models,
ccelerate atherosclerosis (83).
Nicotine in cigarette smoke is probably the most studied
omponent. Although nicotine plays a major role in
moking-related increases in cardiac output, heart rate, and
lood pressure, its role in CS-related athero-thrombotic
isease remains controversial (17,84–89). Nicotine expo-
ure alone had been reported to cause no change, a decrease,
r an increase in EDV or NO availability (85–88). In
arious models, although high doses of nicotine favor
therogenic changes, the majority of current evidence sug-
ests that nicotine, at concentrations similar to a smoker’s
lood level, has a minor effect on the initiation or propaga-
ion of atherosclerosis (17,85). Similarly, the effect of
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brinogen, or t-PA, PAI-1 appears to be insignificant in the
etting of smoking (17,84,89). As mentioned earlier, nico-
ine is the known addictive substance in cigarette smoke,
nd its addictive qualities likely perpetuate exposure to the
ther more detrimental components.
Currently, free radical-mediated oxidative stress is emerg-
ng as the pivotal step for the development of atherosclerosis
90–92). In a setting of CS, free radicals could arise from: 1)
he gas or tar phase of cigarette smoke; 2) circulating or in
itu-activated macrophages and neutrophils; and 3) endog-
nous sources of reactive oxygen species such as uncoupled
NOS, xanthine oxidase, and the mitochondrial electron
ransport chain (16–20,39,93–96). A reaction between free
adicals such as superoxide and NO not only decreases NO
vailability but also generates peroxynitrite, which further
nhances the cellular oxidative stress (91). Increased oxida-
ive stress with the loss of the protective effect of NO tips
he cellular balance towards a proatherogenic and pro-
hrombotic milieu (92,97). Many of the abnormalities
escribed above, including endothelial dysfunction, proin-
ammatory effects on the vessel wall, prothrombotic effects
uch as increased platelet reactivity, reduced endogenous
brinolysis, and lipid peroxidation, can largely be explained
y the effects of increased oxidative stress (16–20,94–96).
urthermore, antioxidants or agents that reduced the oxi-
ative stress or increased NO availability have been shown
o either improve or reverse the proatherogenic, proinflam-
atory, and prothrombotic attributes associated with CS
39,98–100).
ONLINEAR DOSE EFFECT OF
MOKING ON CARDIOVASCULAR FUNCTION
lthough the association between CS and cardiovascular
isk has clearly been demonstrated, an unanswered question
s whether or not there is a linear dose effect. Several recent
arge epidemiologic studies showing a trend for more
ardiovascular events in heavier active smokers have failed to
nd a significant dose-dependent correlation between car-
iovascular risk and the number of cigarettes smoked or the
ack-years of exposure (9,14). More recently, heavy and
ight active smokers had a similar decrease in brachial artery
DV and similar abnormalities of NO biosynthesis (101).
imilarly, even with passive smoking, certain athero-
hrombotic markers such as a reduced EDV and increased
latelet activation were similar to that of active smoking
32,34,102). The data presented above suggest that the
nderlying biochemical and cellular processes may become
aturated with small doses of toxic components from ciga-
ette smoke causing a nonlinear dose-response on cardio-
ascular function. The exact mechanisms involved require
urther study.
onclusions. Epidemiologic studies have established
orldwide that cigarette smoke exposure is an importantause of cardiovascular morbidity and mortality. Clinicalnd experimental studies indicate that either active or
assive exposure promotes vasomotor dysfunction, athero-
enesis, and thrombosis in multiple vascular beds. Although
he precise mechanisms responsible remain undetermined,
ree radical-mediated oxidative stress appears to play a
entral role in CS-mediated athero-thrombotic diseases.
hese free radicals could potentially arise directly from
igarette smoke and indirectly from endogenous sources as
ell. Furthermore, potentiated by multiple prothrombotic
nd antifibrinolytic effects, intravascular thrombosis is the
redominant cause of acute cardiovascular events. An in-
reasing body of epidemiologic, clinical, and experimental
ata also suggest that the pathophysiologic effects of ciga-
ette smoke exposure on cardiovascular function may be
onlinear. Future studies investigating the potential ciga-
ette smoke-inducible endogenous cellular mechanisms
ould further our understanding of the complex pathobiol-
gy of cigarette smoke and cardiovascular dysfunction.
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